Literature DB >> 6274955

Immunoglobulin expression by human B lymphocytes clonally transformed by Epstein Barr virus.

N A Brown, G Miller.   

Abstract

Epstein Barr virus (EBV) immortalizes human B lymphocytes, resulting in long-term lymphoblastoid cell lines. To date, such cell lines have typically been derived by suspension culture of mixed mononuclear cells, infected in vivo or in vitro with EBV. We have derived 208 lymphoblastoid lines by clonal transformation of peripheral blood lymphocytes from 3 neonates, 3 normal adults, and 1 patient with systemic lupus erythematosus (SLE), utilizing colony formation in agarose and then separate propagation of the colonies in liquid medium. A total of 180 lines have been analyzed for expression of cytoplasmic and/or secreted immunoglobulin isotypes. Such analysis reveals that 167 (92%) of the lines are monoclonal with respect to isotype expression. All clonally derived lines from neonates produce only IgM. Most clonal transformants from normal adults also produce IgM (81%), but clones producing IgG (16%) or IgA (3%) were also found. Clonal transformation of lymphocytes from the SLE patient revealed a shift in isotype expression, with increased numbers of IgG-secreting clones (48%) and IgA-secreting clones (13%). The data support the use of EBV-mediated clonal transformation as a probe for the analysis of states of isotype differentiation among circulating B cells, and as a method for deriving immortalized, monoclonal human B cell lines.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6274955

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  B-lymphocyte subpopulations are equally susceptible to Epstein-Barr virus infection, irrespective of immunoglobulin isotype expression.

Authors:  Barbro Ehlin-Henriksson; John Gordon; George Klein
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

2.  B-cell lymphoproliferation and lymphomagenesis are associated with clonotypic intracellular terminal regions of the Epstein-Barr virus.

Authors:  N A Brown; C R Liu; Y F Wang; C R Garcia
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

3.  Generation of mouse-human hybridomas secreting antibodies against peanut allergen Ara h1.

Authors:  Hiroshi Shinmoto; Yasunori Naganawa; Michie Shimmoto; Soheila J Maleki
Journal:  Cytotechnology       Date:  2005-06-16       Impact factor: 2.058

Review 4.  The human immune response to red blood cell antigens as revealed by repertoire cloning.

Authors:  D L Siegel
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

5.  Immunoglobulin JH, C mu, and C gamma gene rearrangements in human B lymphocytes clonally transformed by Epstein-Barr virus.

Authors:  N A Brown; C Liu; J R Berenson; C R Garcia; R Wang; K L Calame
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

6.  Self-reactive B lymphocytes detected in young adults, children and newborns after in vitro infection with Epstein-Barr virus.

Authors:  H Uhlig; G Rutter; R Dernick
Journal:  Clin Exp Immunol       Date:  1985-10       Impact factor: 4.330

7.  Requirements for growth of Epstein-Barr virus-transformed cells at low cell densities.

Authors:  R F Tiebout; R W Sauerwein; W G van der Meer; F van Boxtel-Oosterhof; W P Zeijlemaker
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

8.  Construction and testing of mouse--human heteromyelomas for human monoclonal antibody production.

Authors:  N N Teng; K S Lam; F Calvo Riera; H S Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

Review 9.  Human monoclonal antibodies.

Authors:  S P Cole; B G Campling; T Atlaw; D Kozbor; J C Roder
Journal:  Mol Cell Biochem       Date:  1984-06       Impact factor: 3.396

Review 10.  Epstein-Barr virus infection and associated diseases in children. I. Pathogenesis, epidemiology and clinical aspects.

Authors:  V Schuster; H W Kreth
Journal:  Eur J Pediatr       Date:  1992-10       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.